# S8 Review / Revision: Simulated Peer Review and Revision Roadmap

## Stage Purpose

This S8 checkpoint reviews the S7b citation-clean manuscript as if it were a first submission to a mid-tier to upper-mid-tier epidemiology, public health, or diabetes journal. The purpose is to identify reviewer-facing weaknesses and produce a concrete revision roadmap.

Reviewed manuscript:

- `checkpoints/stage-S7b-citation-clean-draft.md`

This stage is read-only with respect to the manuscript. It does not revise the manuscript text.

## Reviewer Configuration

| Reviewer | Role | Simulated expertise |
|---|---|---|
| EIC | Handling editor | Population health / chronic disease epidemiology editor |
| Reviewer 1 | Methodology reviewer | Complex survey methods, NHANES, epidemiologic regression |
| Reviewer 2 | Domain reviewer | Diabetes epidemiology and screening |
| Reviewer 3 | Cross-disciplinary reviewer | Public health implementation, screening equity, AI/data science positioning |
| Reviewer 4 | Devil's advocate | Core-argument stress test and overclaim detection |

## Editorial Decision

**Major Revision**

The manuscript is scientifically salvageable and has a coherent, cautious research question. It uses a recognized public dataset, appropriate complex-survey methods, verified references, and a defensible cross-sectional framing. However, it is not yet submission-ready because the paper still reads partly like a well-developed draft rather than a journal manuscript: tables and figures are placeholders, the novelty claim needs sharper positioning, statistical reporting needs more NHANES-specific detail, and the Discussion should be tightened around a clearer contribution.

The likely editorial outcome is **Major Revision / Resubmit after substantial revision**, not rejection, if submitted to a realistic specialty journal. For a high-impact diabetes journal, the likely decision would be rejection or transfer because the incremental novelty is modest.

## Reviewer Summary

| Reviewer | Recommendation | Confidence |
|---|---|---:|
| EIC | Major Revision | 4/5 |
| Reviewer 1 - Methodology | Major Revision | 4/5 |
| Reviewer 2 - Domain | Major Revision | 4/5 |
| Reviewer 3 - Cross-disciplinary | Minor-to-Major Revision | 3/5 |
| Reviewer 4 - Devil's Advocate | Major Revision | 4/5 |

## EIC Review Report

### Summary Assessment

The manuscript addresses an understandable and relevant public health question: among adults who do not report diagnosed diabetes, what proportion have diabetes-range HbA1c and what routine cardiometabolic features characterize them? The paper is coherent and responsibly avoids causal and diagnostic overclaiming. Its strongest feature is its practical screening-gap framing and the use of NHANES survey weights.

The main editorial concern is positioning. NHANES-based undiagnosed diabetes studies already exist, and the paper must make clearer why a single-cycle 2017-2018, HbA1c-focused, correlates-oriented analysis adds value. The manuscript is also not yet presented as a complete submission because tables and figures are placeholders. A journal editor would likely send this out only after visible tables, figure, concise novelty statement, and journal-ready formatting are in place.

### Strengths

1. **Clear denominator**: The paper focuses on self-reported non-diabetic adults, which matches a screening-gap question better than a general adult population denominator.
2. **Cautious conclusion**: The manuscript repeatedly distinguishes HbA1c-defined epidemiologic categories from clinical diagnosis.
3. **Practical variables**: Waist circumference and non-HDL cholesterol are routine, interpretable measures.
4. **Citation layer improved**: S7b replaced placeholders with a verified reference list.

### Weaknesses

1. **Novelty is still understated and vulnerable**: The Introduction says prior studies exist but does not sharply define the incremental contribution.
2. **Incomplete submission package**: Tables and figures are placeholders, which would block meaningful editorial review.
3. **Discussion is long relative to the results**: Several sections repeat cautionary language and could be compressed.
4. **Journal fit needs realism**: This is better suited to a focused public health / chronic disease journal than a high-impact diabetes specialty journal.

### EIC Required Changes

- Add a short final Introduction paragraph explicitly stating the incremental contribution in one or two sentences.
- Insert actual Table 1, Table 2, Figure 1, and Figure 2 before any journal submission.
- Shorten Discussion by 15-25%, especially repeated limitations and general AI positioning.
- Decide the target journal family before final formatting.

## Reviewer 1: Methodology Review

### Summary Assessment

The analytic design is appropriate for an exploratory cross-sectional NHANES analysis. The use of MEC weights, strata, and PSUs is correct for an outcome based on examination and laboratory variables. The choice of a parsimonious model is defensible because the single-cycle design limits design degrees of freedom. The main methodological weaknesses are reporting completeness rather than fatal analytic flaws. The manuscript should more explicitly report missingness, model sample size, design degrees of freedom, fasting-glucose subsample considerations, and sensitivity-model specifications.

### Strengths

1. **Appropriate complex survey handling**: The Methods state use of `WTMEC2YR`, `SDMVSTRA`, and `SDMVPSU`.
2. **Correct caution about single-cycle model complexity**: The draft does not force a parameter-heavy full model.
3. **Sensitivity analysis is conceptually useful**: HbA1c-only vs HbA1c-or-FPG directly addresses definition sensitivity.
4. **Effect estimates and confidence intervals are reported**: The main model reports ORs and 95% CIs.

### Weaknesses

1. **Missing-data reporting is insufficient**: The flow diagram gives HbA1c availability, but covariate missingness and model `n=3621` are not clearly reconciled with the analytic sample `n=4004`.
2. **FPG sensitivity may require fasting-weight discussion**: The manuscript uses a fasting glucose sensitivity definition but does not explain whether fasting subsample weights were required or whether FPG was treated only as an available-measure sensitivity outcome.
3. **Design degrees of freedom are not reported in the manuscript**: The S3b output indicates design df = 15, which is relevant to model parsimony and CI interpretation.
4. **No explicit STROBE-style reporting**: The manuscript should include reporting guideline alignment, even if only in a checklist or methods note.
5. **No code/data availability statement**: Public NHANES data are available, but the analysis code and derived analytic dataset status should be stated.

### Methodology Required Changes

- Add a missingness paragraph: analysis sample, model sample, and reasons for covariate exclusion.
- Add Table 1 with unweighted `n`, weighted percentages/means, and missingness where relevant.
- Add a note under Statistical Analysis: design degrees of freedom and why model parsimony was selected.
- Clarify fasting glucose sensitivity weighting. If fasting subsample weights were not used, either rerun sensitivity with appropriate fasting weights or explicitly frame this as an exploratory available-data sensitivity with limitations.
- Add a data/code availability statement.

## Reviewer 2: Domain Review

### Summary Assessment

The domain framing is generally accurate. The manuscript correctly distinguishes undiagnosed diabetes surveillance, self-reported diagnosis, HbA1c/FPG definition differences, and clinical confirmation rules. The 17-item reference list is now credible. The main domain issue is that the literature review is still too narrow for a scholarly diabetes epidemiology manuscript. The paper needs a more precise comparison to prior NHANES studies and a stronger explanation of why 2017-2018 alone is worth analyzing. The race/ethnicity discussion is appropriately cautious but would benefit from more direct evidence on screening access and diabetes detection disparities.

### Strengths

1. **Correct diagnostic boundary**: The paper does not equate one HbA1c with confirmed clinical diabetes.
2. **Good use of Fang et al. and Menke et al. context**: Prior trend and burden studies are now represented.
3. **Balanced adiposity interpretation**: Waist circumference is presented as a correlate, not as a diagnostic substitute.
4. **Cautious race/ethnicity language**: The manuscript avoids essentialist framing.

### Weaknesses

1. **Race/ethnicity explanation remains under-sourced**: The text is careful but still needs direct citations on screening inequity or access to care.
2. **Prediabetes is included but under-integrated**: The prediabetes result is prominent numerically but not fully integrated into the manuscript's main contribution.
3. **Non-HDL cholesterol literature may be adjacent rather than directly matched**: Some references are about non-HDL-to-HDL ratio or incident diabetes, while this study uses non-HDL cholesterol and undiagnosed diabetes.
4. **Single-cycle rationale needs sharpening**: Reviewers may ask why not pool multiple NHANES cycles.

### Domain Required Changes

- Add 2-3 targeted citations on diabetes screening access, health care contact, or racial/ethnic detection disparities.
- Explain why the paper uses 2017-2018 only: training/demo simplicity is not acceptable for the manuscript; scientific rationale must be stated or the limitation must be prominent.
- Decide whether prediabetes is a secondary outcome or contextual result; then align Abstract, Results, and Discussion accordingly.
- Keep non-HDL cholesterol interpretation modest unless additional directly matched literature is added.

## Reviewer 3: Cross-Disciplinary / Practical Impact Review

### Summary Assessment

The manuscript has practical appeal because it avoids overbuilding an AI prediction model and instead presents an epidemiologic foundation for future screening research. This is a strength for a medical AI training context and for cautious public health interpretation. However, the paper should separate manuscript goals from training/demo goals. The published article should not imply that this analysis is a clinical screening tool or a deployable AI foundation. The AI discussion is currently useful but could be shorter and more precise.

### Strengths

1. **Appropriate restraint around AI**: The manuscript explicitly says it is not a validated prediction model.
2. **Screening-gap framing is accessible**: It connects epidemiologic findings to public health practice without making clinical rules.
3. **Routine-measure emphasis is practical**: Waist circumference and non-HDL cholesterol are understandable to non-specialist readers.

### Weaknesses

1. **Implementation implications are still vague**: The manuscript says routine measures may characterize screening gaps but does not specify what future study would test.
2. **AI/data science paragraph may distract**: It may be valuable for training, but reviewers may see it as tangential unless the target journal welcomes digital health framing.
3. **Equity framing needs operational variables**: Insurance, usual source of care, health care utilization, or screening history would strengthen the argument, but they are not modeled.

### Cross-Disciplinary Required Changes

- Reframe AI paragraph as one concise future-work sentence, unless targeting a digital health journal.
- Add a future-research sentence specifying that predictive modeling would require pooled cycles, train/test split, calibration, fairness assessment, and external validation.
- If feasible in a later analytic revision, consider adding health care access variables. If not feasible, state this clearly as a limitation.

## Reviewer 4: Devil's Advocate Review

### Core Challenge

The strongest counter-argument is: **What does this manuscript add beyond existing NHANES undiagnosed diabetes surveillance papers?** The study's core estimates are lower than recent national surveillance estimates because the denominator and definition differ; this is valid, but it also makes the paper's headline contribution narrower. If the manuscript cannot articulate a sharper contribution, reviewers may view it as a secondary teaching/demo analysis rather than a publishable SCI article.

### Stress-Test Findings

1. **Novelty risk**: "Routine correlates of undiagnosed diabetes" may be too expected unless the manuscript frames itself as a deliberately parsimonious screening-gap profile.
2. **Model events risk**: There are 150 outcome cases, but the weighted survey design has limited df; the primary model is still somewhat ambitious with race/ethnicity categories.
3. **Outcome definition risk**: HbA1c-only undiagnosed diabetes is reproducible but conservative and may miss glucose-defined cases.
4. **Overinterpretation risk**: Phrases like "screening gaps" are acceptable, but they depend on unmeasured screening history and health care access.
5. **Submission readiness risk**: Placeholder tables/figures make the manuscript incomplete.

### Devil's Advocate Required Changes

- Add a "Why this study adds value" statement that does not overclaim novelty.
- State that "screening gap" is inferred from discordance between self-report and lab values, not directly measured screening access.
- Keep race/ethnicity results as descriptive flags for future equity research, not as individual-level risk guidance.
- Ensure the final manuscript has all tables and figures embedded.

## Consensus Analysis

### Consensus Points

1. **The paper is salvageable and coherent**: All reviewers agree the study is scientifically plausible and cautiously framed.
2. **Major revision is needed before submission**: All reviewers identify missing tables/figures and reporting gaps.
3. **Complex survey reporting must be strengthened**: Reviewers agree the methods are broadly appropriate but underreported.
4. **Novelty must be sharpened**: All reviewers agree that prior NHANES undiagnosed diabetes literature creates a publication challenge.
5. **Clinical/causal caution is a strength**: All reviewers agree the manuscript avoids the most dangerous overclaims.

### Main Disagreement

Reviewer 3 is somewhat more optimistic because the screening-gap and AI-training positioning has practical value. The EIC and Devil's Advocate are stricter because journals will judge novelty and completeness rather than training usefulness. The editor's resolution is to treat the paper as **Major Revision**: promising but not ready.

## Required Revisions

| # | Revision item | Source | Severity | Section | Estimated effort |
|---|---|---|---|---|---:|
| R1 | Insert actual Table 1, Table 2, Figure 1, Figure 2 | EIC, R1, R4 | Critical | Results | 1-2 days |
| R2 | Add missingness/model sample reconciliation | R1 | Major | Methods/Results | 0.5-1 day |
| R3 | Clarify FPG sensitivity weighting and fasting subsample handling | R1 | Major | Methods/Limitations | 0.5-1 day, or longer if rerun |
| R4 | Sharpen novelty and contribution statement | EIC, R2, R4 | Major | Introduction/Discussion | 0.5 day |
| R5 | Add design df/model parsimony reporting | R1, R4 | Major | Statistical Analysis/Results | 0.5 day |
| R6 | Add 2-3 targeted equity/screening-access citations or downgrade equity discussion | R2, R3 | Major | Discussion | 0.5-1 day |
| R7 | Tighten Discussion and remove repeated cautionary language | EIC, R3 | Major | Discussion | 0.5-1 day |
| R8 | Add data/code availability and ethics/public-use data statement | R1 | Major | End matter/Methods | 0.5 day |

## Suggested Revisions

| # | Revision item | Priority | Expected improvement |
|---|---|---|
| S1 | Add a STROBE checklist note or supplementary checklist | P2 | Improves epidemiology reporting credibility |
| S2 | Decide whether prediabetes is secondary outcome or contextual result | P2 | Improves manuscript coherence |
| S3 | Reduce AI/data science discussion to one concise paragraph | P2 | Reduces distraction for non-digital-health journals |
| S4 | Add a target-journal formatting pass after revision | P3 | Improves submission readiness |
| S5 | Consider a supplementary model excluding or simplifying race/ethnicity categories if df concerns persist | P2 | Addresses model stability concerns |

## Revision Roadmap

### Priority 1 - Submission Completeness

- [ ] Generate and insert Figure 1 from `results/S3/flow_counts.csv`.
- [ ] Generate and insert Figure 2 from `results/S3/weighted_prevalence_subgroups.csv`.
- [ ] Format Table 1 from `results/S3/table1_weighted_by_outcome.csv`.
- [ ] Format Table 2 from `results/S3b/table2_final_main_waist_model.csv`.
- [ ] Add Supplementary Tables for BMI, categorical model, and HbA1c/FPG sensitivity analysis.

### Priority 2 - Statistical Reporting

- [ ] Reconcile analytic sample `n=4004` with model sample `n=3621`.
- [ ] Report missingness for key covariates.
- [ ] Report design df = 15 for the final model and explain parsimony.
- [ ] Clarify fasting glucose sensitivity weights/subsample.
- [ ] Add data/code availability and public-use data ethics statement.

### Priority 3 - Argument and Literature

- [ ] Add a precise contribution paragraph at the end of Introduction.
- [ ] Add targeted screening equity citations or soften the equity interpretation.
- [ ] Decide prediabetes status: secondary outcome vs context.
- [ ] Keep non-HDL interpretation as cardiometabolic profiling, not screening rule.

### Priority 4 - Style and Fit

- [ ] Shorten Discussion by 15-25%.
- [ ] Remove repeated "not causal / not diagnostic" statements while retaining one strong version in Abstract, Methods, and Limitations.
- [ ] Choose target journal family and adjust reference style/end matter.
- [ ] Prepare response-to-reviewers template after revisions.

## Estimated Effort

| Revision level | Estimated time |
|---|---:|
| Minimum S8-to-S9 cleanup | 2-3 days |
| Strong manuscript revision | 5-7 days |
| If rerunning sensitivity analyses with fasting weights or adding health care access variables | 7-10 days |

## S8 Decision

S8 is complete. The manuscript should not proceed directly to S9 finalization until the required revisions are addressed. The recommended next stage is an **S8b revision implementation stage** focused on tables/figures, statistical reporting, and argument tightening.

## ARS Checkpoint

阶段：S8 - Review / Revision  
状态：complete, awaiting user confirmation  
本阶段交付物：
- `checkpoints/stage-S8-review-revision.md`

关键决定：
- 模拟审稿结论为 **Major Revision**。
- 稿件可救，不建议放弃；但不应直接进入 S9 定稿。
- 下一步优先做 S8b：按修订路线图实施修改。

风险与限制：
- 本阶段没有改写正文。
- 审稿判断基于当前 S7b 草稿和本地分析结果，不等同于真实期刊决定。
- 目标期刊尚未确定，因此格式建议仍是通用 SCI/公共卫生医学期刊标准。

下一阶段建议：S8b - Revision Implementation  
需要你确认：是否进入 S8b，开始按路线图修改正文、表格和图？
